| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Trials, Phase I as Topic | 11 | 2019 | 155 | 3.550 |
Why?
|
| Research Design | 13 | 2023 | 594 | 3.460 |
Why?
|
| Bayes Theorem | 23 | 2023 | 361 | 3.320 |
Why?
|
| Maximum Tolerated Dose | 7 | 2023 | 270 | 2.410 |
Why?
|
| Computer Simulation | 16 | 2023 | 1078 | 2.110 |
Why?
|
| Models, Statistical | 16 | 2019 | 574 | 2.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 7 | 2019 | 199 | 1.640 |
Why?
|
| Software | 8 | 2018 | 654 | 1.510 |
Why?
|
| Apoptosis | 10 | 2019 | 1683 | 1.440 |
Why?
|
| Sequence Analysis, DNA | 5 | 2015 | 853 | 1.250 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2023 | 1961 | 1.250 |
Why?
|
| Neoplasms | 14 | 2023 | 2898 | 1.240 |
Why?
|
| Algorithms | 16 | 2019 | 1830 | 1.180 |
Why?
|
| Probability | 8 | 2021 | 355 | 1.120 |
Why?
|
| Cell Proliferation | 9 | 2018 | 1578 | 1.090 |
Why?
|
| Gene Expression Profiling | 10 | 2019 | 1384 | 1.020 |
Why?
|
| Data Interpretation, Statistical | 4 | 2011 | 297 | 0.980 |
Why?
|
| Genomics | 8 | 2019 | 720 | 0.950 |
Why?
|
| Stomach Neoplasms | 4 | 2020 | 266 | 0.860 |
Why?
|
| Antineoplastic Agents | 9 | 2019 | 2360 | 0.840 |
Why?
|
| Computational Biology | 7 | 2019 | 528 | 0.730 |
Why?
|
| Rubus | 1 | 2019 | 1 | 0.690 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 69 | 0.650 |
Why?
|
| Monascus | 1 | 2018 | 2 | 0.650 |
Why?
|
| Robotics | 1 | 2021 | 267 | 0.650 |
Why?
|
| Phenols | 1 | 2018 | 40 | 0.630 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2016 | 170 | 0.610 |
Why?
|
| Signal Transduction | 8 | 2019 | 3241 | 0.610 |
Why?
|
| Models, Biological | 6 | 2019 | 1749 | 0.580 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2016 | 49 | 0.570 |
Why?
|
| Ornithogalum | 1 | 2016 | 1 | 0.570 |
Why?
|
| Biometry | 3 | 2017 | 66 | 0.560 |
Why?
|
| Humans | 65 | 2023 | 86643 | 0.560 |
Why?
|
| Sample Size | 3 | 2019 | 130 | 0.550 |
Why?
|
| Biological Products | 1 | 2018 | 143 | 0.540 |
Why?
|
| Mosaicism | 1 | 2015 | 67 | 0.530 |
Why?
|
| Genome, Human | 2 | 2020 | 756 | 0.510 |
Why?
|
| Pattern Recognition, Automated | 2 | 2008 | 217 | 0.510 |
Why?
|
| Plant Extracts | 2 | 2014 | 244 | 0.510 |
Why?
|
| Cluster Analysis | 5 | 2019 | 369 | 0.510 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 2903 | 0.510 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2007 | 689 | 0.510 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2016 | 384 | 0.510 |
Why?
|
| G2 Phase | 2 | 2014 | 34 | 0.500 |
Why?
|
| Sequence Analysis, RNA | 3 | 2019 | 217 | 0.490 |
Why?
|
| Liliaceae | 1 | 2014 | 1 | 0.490 |
Why?
|
| Araceae | 1 | 2014 | 1 | 0.490 |
Why?
|
| Plant Tubers | 1 | 2014 | 1 | 0.490 |
Why?
|
| Isodon | 1 | 2014 | 1 | 0.490 |
Why?
|
| Diterpenes, Kaurane | 1 | 2014 | 1 | 0.490 |
Why?
|
| S Phase Cell Cycle Checkpoints | 1 | 2014 | 3 | 0.490 |
Why?
|
| Organoselenium Compounds | 1 | 2014 | 4 | 0.490 |
Why?
|
| Carrageenan | 1 | 2014 | 9 | 0.490 |
Why?
|
| Epirubicin | 1 | 2014 | 14 | 0.490 |
Why?
|
| Cyclin B1 | 1 | 2014 | 17 | 0.490 |
Why?
|
| Alkaloids | 1 | 2014 | 45 | 0.480 |
Why?
|
| Fas Ligand Protein | 1 | 2014 | 49 | 0.480 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2014 | 43 | 0.480 |
Why?
|
| Internet | 2 | 2015 | 312 | 0.480 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2015 | 176 | 0.480 |
Why?
|
| Sequence Alignment | 2 | 2012 | 351 | 0.470 |
Why?
|
| Haplotypes | 1 | 2015 | 642 | 0.460 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 114 | 0.460 |
Why?
|
| Biostatistics | 1 | 2013 | 20 | 0.450 |
Why?
|
| Liver Neoplasms | 3 | 2016 | 736 | 0.440 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2021 | 3362 | 0.430 |
Why?
|
| Cell Division | 1 | 2014 | 696 | 0.430 |
Why?
|
| Flow Cytometry | 7 | 2016 | 679 | 0.410 |
Why?
|
| Ethanol | 1 | 2014 | 249 | 0.400 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2012 | 93 | 0.380 |
Why?
|
| Hemangioma, Cavernous | 2 | 2021 | 69 | 0.380 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 1169 | 0.380 |
Why?
|
| RNA | 2 | 2012 | 560 | 0.380 |
Why?
|
| T-Lymphocytes | 2 | 2019 | 1195 | 0.370 |
Why?
|
| Precision Medicine | 2 | 2016 | 395 | 0.360 |
Why?
|
| Hep G2 Cells | 3 | 2014 | 48 | 0.360 |
Why?
|
| Cell Line, Tumor | 11 | 2019 | 2426 | 0.350 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2009 | 24 | 0.340 |
Why?
|
| Endpoint Determination | 1 | 2009 | 60 | 0.340 |
Why?
|
| Tumor Cells, Cultured | 4 | 2014 | 1041 | 0.340 |
Why?
|
| Oxazoles | 1 | 2008 | 19 | 0.330 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2008 | 33 | 0.330 |
Why?
|
| Medical Oncology | 2 | 2023 | 359 | 0.330 |
Why?
|
| Fluoroquinolones | 1 | 2008 | 22 | 0.330 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 2 | 2022 | 223 | 0.330 |
Why?
|
| Cell Cycle | 5 | 2014 | 502 | 0.330 |
Why?
|
| Gene Expression Regulation | 3 | 2008 | 1920 | 0.320 |
Why?
|
| MicroRNAs | 4 | 2022 | 534 | 0.320 |
Why?
|
| Models, Theoretical | 3 | 2018 | 482 | 0.310 |
Why?
|
| Lymph Nodes | 3 | 2019 | 533 | 0.300 |
Why?
|
| Mutation | 9 | 2019 | 3968 | 0.290 |
Why?
|
| Naphthols | 1 | 2006 | 4 | 0.290 |
Why?
|
| Azo Compounds | 1 | 2006 | 13 | 0.290 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 859 | 0.280 |
Why?
|
| Hodgkin Disease | 3 | 2012 | 177 | 0.280 |
Why?
|
| Mice | 12 | 2022 | 11352 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 458 | 0.270 |
Why?
|
| Genome | 4 | 2018 | 372 | 0.270 |
Why?
|
| Blotting, Western | 5 | 2014 | 782 | 0.270 |
Why?
|
| Proteomics | 2 | 2018 | 212 | 0.260 |
Why?
|
| Oleanolic Acid | 1 | 2005 | 13 | 0.260 |
Why?
|
| Cell Physiological Phenomena | 1 | 2005 | 24 | 0.260 |
Why?
|
| Prodrugs | 1 | 2005 | 46 | 0.260 |
Why?
|
| Animals | 18 | 2022 | 26582 | 0.250 |
Why?
|
| Drug Compounding | 1 | 2005 | 78 | 0.240 |
Why?
|
| Proteome | 1 | 2005 | 124 | 0.240 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2016 | 456 | 0.240 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2012 | 85 | 0.220 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 1169 | 0.220 |
Why?
|
| Caspase 3 | 2 | 2016 | 159 | 0.220 |
Why?
|
| Circulating MicroRNA | 1 | 2022 | 12 | 0.220 |
Why?
|
| Genetic Vectors | 2 | 2019 | 439 | 0.210 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 1047 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2016 | 1313 | 0.200 |
Why?
|
| Brain Neoplasms | 3 | 2021 | 763 | 0.200 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 916 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 185 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2019 | 1204 | 0.200 |
Why?
|
| Stromal Cells | 2 | 2019 | 143 | 0.190 |
Why?
|
| Perfusion Imaging | 1 | 2021 | 50 | 0.190 |
Why?
|
| Cohort Studies | 4 | 2021 | 2767 | 0.190 |
Why?
|
| Benzamides | 2 | 2011 | 229 | 0.190 |
Why?
|
| Brain Stem | 1 | 2021 | 165 | 0.190 |
Why?
|
| Neoplasm Proteins | 3 | 2011 | 532 | 0.190 |
Why?
|
| Biomarkers | 3 | 2021 | 1718 | 0.180 |
Why?
|
| Oncolytic Viruses | 1 | 2019 | 23 | 0.180 |
Why?
|
| STAT4 Transcription Factor | 1 | 2019 | 10 | 0.180 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2019 | 36 | 0.180 |
Why?
|
| Male | 19 | 2021 | 40965 | 0.170 |
Why?
|
| Prostatic Neoplasms | 3 | 2019 | 1721 | 0.170 |
Why?
|
| Myeloid Cells | 1 | 2019 | 98 | 0.170 |
Why?
|
| Oncolytic Virotherapy | 1 | 2019 | 41 | 0.170 |
Why?
|
| Adenoviridae | 2 | 2019 | 345 | 0.170 |
Why?
|
| Female | 19 | 2021 | 44532 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2021 | 268 | 0.170 |
Why?
|
| Hepatitis B, Chronic | 1 | 2019 | 32 | 0.170 |
Why?
|
| Protective Agents | 1 | 2019 | 33 | 0.170 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2019 | 66 | 0.170 |
Why?
|
| Epistasis, Genetic | 2 | 2017 | 86 | 0.160 |
Why?
|
| Interferon-alpha | 1 | 2019 | 233 | 0.160 |
Why?
|
| Immunity | 1 | 2019 | 136 | 0.160 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 307 | 0.160 |
Why?
|
| Gene Regulatory Networks | 2 | 2018 | 296 | 0.160 |
Why?
|
| Lymphoma | 2 | 2010 | 262 | 0.160 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 190 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2019 | 92 | 0.160 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 321 | 0.160 |
Why?
|
| Statistical Distributions | 1 | 2017 | 9 | 0.160 |
Why?
|
| Phenotype | 4 | 2019 | 2378 | 0.160 |
Why?
|
| Hyperglycemia | 1 | 2019 | 176 | 0.160 |
Why?
|
| Prostatic Hyperplasia | 1 | 2019 | 88 | 0.160 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1805 | 0.160 |
Why?
|
| Cerebral Hemorrhage | 1 | 2021 | 325 | 0.160 |
Why?
|
| Information Storage and Retrieval | 1 | 2018 | 120 | 0.150 |
Why?
|
| Antioxidants | 1 | 2019 | 223 | 0.150 |
Why?
|
| Base Sequence | 5 | 2015 | 2330 | 0.150 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 1464 | 0.150 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 301 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2018 | 318 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 930 | 0.140 |
Why?
|
| Cytochromes c | 1 | 2016 | 27 | 0.140 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 29 | 0.140 |
Why?
|
| Membrane Proteins | 2 | 2015 | 1196 | 0.140 |
Why?
|
| Documentation | 1 | 2016 | 98 | 0.140 |
Why?
|
| Decision Theory | 1 | 2015 | 3 | 0.140 |
Why?
|
| Saponins | 1 | 2016 | 41 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 2 | 2014 | 645 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2020 | 7993 | 0.130 |
Why?
|
| Liver | 2 | 2019 | 1230 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 2271 | 0.130 |
Why?
|
| Likelihood Functions | 3 | 2015 | 251 | 0.130 |
Why?
|
| Antiviral Agents | 1 | 2019 | 510 | 0.130 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2015 | 46 | 0.130 |
Why?
|
| Carcinoma, Lobular | 1 | 2015 | 81 | 0.130 |
Why?
|
| Time Factors | 3 | 2019 | 5210 | 0.130 |
Why?
|
| Molecular Sequence Data | 4 | 2015 | 3030 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 469 | 0.130 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2014 | 4 | 0.130 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2014 | 12 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 79 | 0.120 |
Why?
|
| Markov Chains | 4 | 2018 | 125 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 157 | 0.120 |
Why?
|
| Cyclin A | 1 | 2014 | 28 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 1991 | 0.120 |
Why?
|
| cdc25 Phosphatases | 1 | 2014 | 18 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2014 | 25 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 294 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 552 | 0.120 |
Why?
|
| CDC2 Protein Kinase | 1 | 2014 | 45 | 0.120 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 813 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2015 | 260 | 0.120 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 106 | 0.120 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 63 | 0.120 |
Why?
|
| Radiography | 1 | 2015 | 813 | 0.120 |
Why?
|
| Cell Survival | 2 | 2014 | 969 | 0.120 |
Why?
|
| Central Nervous System Depressants | 1 | 2014 | 45 | 0.120 |
Why?
|
| Cytokines | 4 | 2019 | 776 | 0.120 |
Why?
|
| Proteins | 1 | 2019 | 777 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 1376 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 316 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2016 | 319 | 0.110 |
Why?
|
| Molecular Structure | 1 | 2014 | 287 | 0.110 |
Why?
|
| tau Proteins | 1 | 2013 | 62 | 0.110 |
Why?
|
| Inflammation | 1 | 2018 | 920 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2014 | 201 | 0.110 |
Why?
|
| Logistic Models | 3 | 2021 | 1186 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 2357 | 0.110 |
Why?
|
| HeLa Cells | 1 | 2014 | 498 | 0.110 |
Why?
|
| Aged | 10 | 2020 | 18415 | 0.110 |
Why?
|
| Epilepsy | 1 | 2016 | 397 | 0.110 |
Why?
|
| Reference Values | 1 | 2014 | 674 | 0.110 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2012 | 42 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2014 | 504 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 49 | 0.100 |
Why?
|
| Adult | 11 | 2021 | 25648 | 0.100 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 94 | 0.100 |
Why?
|
| Middle Aged | 11 | 2021 | 25028 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 1 | 2013 | 203 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2019 | 1981 | 0.100 |
Why?
|
| Trans-Activators | 1 | 2014 | 429 | 0.100 |
Why?
|
| Lymphoma, B-Cell | 1 | 2012 | 103 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 1135 | 0.100 |
Why?
|
| Neoplasm Transplantation | 2 | 2008 | 391 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2232 | 0.100 |
Why?
|
| Sirolimus | 1 | 2012 | 169 | 0.100 |
Why?
|
| Deafness | 1 | 2010 | 47 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 199 | 0.090 |
Why?
|
| Hearing Loss | 1 | 2010 | 56 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2010 | 238 | 0.090 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2009 | 7 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2009 | 35 | 0.090 |
Why?
|
| Pyridines | 1 | 2011 | 310 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2008 | 381 | 0.090 |
Why?
|
| Inflammation Mediators | 2 | 2021 | 154 | 0.080 |
Why?
|
| Alzheimer Disease | 1 | 2013 | 470 | 0.080 |
Why?
|
| Machine Learning | 2 | 2021 | 232 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 370 | 0.080 |
Why?
|
| Betula | 1 | 2008 | 2 | 0.080 |
Why?
|
| Drosophila | 1 | 2013 | 498 | 0.080 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2008 | 47 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1939 | 0.080 |
Why?
|
| Topotecan | 1 | 2008 | 45 | 0.080 |
Why?
|
| Monte Carlo Method | 3 | 2016 | 185 | 0.080 |
Why?
|
| Curcumin | 1 | 2008 | 15 | 0.080 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2008 | 67 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 153 | 0.080 |
Why?
|
| Time | 1 | 2007 | 77 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2011 | 1197 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2010 | 255 | 0.080 |
Why?
|
| Chromosomes, Mammalian | 1 | 2007 | 36 | 0.080 |
Why?
|
| Phthalic Acids | 1 | 2007 | 4 | 0.080 |
Why?
|
| Viral Proteins | 1 | 2009 | 300 | 0.080 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 40 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 189 | 0.080 |
Why?
|
| Protein Interaction Mapping | 1 | 2007 | 82 | 0.080 |
Why?
|
| Drug Dosage Calculations | 1 | 2007 | 16 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2007 | 118 | 0.070 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2007 | 47 | 0.070 |
Why?
|
| Prognosis | 3 | 2021 | 3679 | 0.070 |
Why?
|
| Endocrine Disruptors | 1 | 2007 | 27 | 0.070 |
Why?
|
| Toxicology | 1 | 2006 | 16 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 977 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2016 | 2261 | 0.070 |
Why?
|
| Mice, Nude | 1 | 2008 | 790 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2007 | 2438 | 0.070 |
Why?
|
| Coloring Agents | 1 | 2006 | 64 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 87 | 0.070 |
Why?
|
| Testicular Neoplasms | 1 | 2007 | 105 | 0.070 |
Why?
|
| Models, Genetic | 2 | 2016 | 926 | 0.070 |
Why?
|
| Risk | 1 | 2007 | 674 | 0.070 |
Why?
|
| Gene Transfer Techniques | 2 | 2019 | 152 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 245 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2019 | 418 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 6509 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2009 | 307 | 0.070 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 265 | 0.070 |
Why?
|
| Methylcellulose | 1 | 2005 | 6 | 0.070 |
Why?
|
| Cytosine Deaminase | 1 | 2005 | 9 | 0.070 |
Why?
|
| Salts | 1 | 2005 | 16 | 0.070 |
Why?
|
| Genotype | 2 | 2021 | 1851 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 302 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 1753 | 0.070 |
Why?
|
| DNA, Complementary | 1 | 2006 | 393 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2019 | 615 | 0.060 |
Why?
|
| Biological Availability | 1 | 2005 | 92 | 0.060 |
Why?
|
| Microspheres | 1 | 2005 | 101 | 0.060 |
Why?
|
| Particle Size | 1 | 2005 | 122 | 0.060 |
Why?
|
| Delayed-Action Preparations | 1 | 2005 | 116 | 0.060 |
Why?
|
| Solubility | 1 | 2005 | 177 | 0.060 |
Why?
|
| Epithelial Cells | 2 | 2019 | 669 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2006 | 678 | 0.060 |
Why?
|
| Drug Carriers | 1 | 2005 | 81 | 0.060 |
Why?
|
| Viruses | 1 | 2005 | 78 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2005 | 334 | 0.060 |
Why?
|
| Dogs | 1 | 2005 | 685 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 1801 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2005 | 556 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2018 | 262 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2019 | 8489 | 0.060 |
Why?
|
| Kidney | 1 | 2009 | 1241 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2005 | 342 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2019 | 663 | 0.060 |
Why?
|
| Glioma | 1 | 2005 | 285 | 0.050 |
Why?
|
| KRIT1 Protein | 1 | 2022 | 62 | 0.050 |
Why?
|
| Leukemia | 1 | 2004 | 320 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2014 | 121 | 0.050 |
Why?
|
| Young Adult | 4 | 2019 | 5976 | 0.050 |
Why?
|
| Gene Expression | 2 | 2016 | 1284 | 0.050 |
Why?
|
| Permeability | 1 | 2021 | 137 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2012 | 303 | 0.050 |
Why?
|
| Perfusion | 1 | 2021 | 203 | 0.050 |
Why?
|
| Capillary Permeability | 1 | 2021 | 130 | 0.050 |
Why?
|
| THP-1 Cells | 1 | 2019 | 4 | 0.050 |
Why?
|
| Chemokine CXCL12 | 1 | 2019 | 37 | 0.050 |
Why?
|
| Cell Growth Processes | 1 | 2019 | 83 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2019 | 47 | 0.040 |
Why?
|
| Indoles | 2 | 2012 | 318 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2013 | 1106 | 0.040 |
Why?
|
| Pedigree | 2 | 2015 | 966 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 62 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2021 | 212 | 0.040 |
Why?
|
| Image Enhancement | 2 | 2016 | 563 | 0.040 |
Why?
|
| Seroconversion | 1 | 2019 | 2 | 0.040 |
Why?
|
| Carcinoma, Ductal | 1 | 2019 | 18 | 0.040 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2019 | 11 | 0.040 |
Why?
|
| Hepatitis B e Antigens | 1 | 2019 | 8 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2020 | 111 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 2262 | 0.040 |
Why?
|
| Parotid Neoplasms | 1 | 2019 | 17 | 0.040 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2019 | 17 | 0.040 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2019 | 21 | 0.040 |
Why?
|
| Nucleosides | 1 | 2019 | 22 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2020 | 157 | 0.040 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2019 | 28 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2019 | 55 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2020 | 207 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 135 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 153 | 0.040 |
Why?
|
| Nucleotides | 1 | 2019 | 95 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 187 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 190 | 0.040 |
Why?
|
| China | 1 | 2019 | 228 | 0.040 |
Why?
|
| Testis | 1 | 2019 | 152 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 77 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 266 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2019 | 265 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 134 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 879 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 860 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 159 | 0.040 |
Why?
|
| Virus Replication | 1 | 2019 | 319 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 171 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2007 | 1075 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 357 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 37 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1204 | 0.040 |
Why?
|
| DNA Repair | 1 | 2020 | 356 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2017 | 52 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1019 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 160 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 486 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 272 | 0.040 |
Why?
|
| Ligands | 1 | 2018 | 433 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 1014 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 363 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2018 | 195 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 580 | 0.040 |
Why?
|
| Chicago | 1 | 2020 | 1379 | 0.030 |
Why?
|
| Contrast Media | 1 | 2021 | 1078 | 0.030 |
Why?
|
| Child | 2 | 2019 | 6927 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 151 | 0.030 |
Why?
|
| Audiometry | 1 | 2015 | 16 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2018 | 729 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1686 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 2015 | 117 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1863 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 865 | 0.030 |
Why?
|
| Prostate | 1 | 2018 | 378 | 0.030 |
Why?
|
| Cell Movement | 1 | 2018 | 758 | 0.030 |
Why?
|
| Gene Components | 1 | 2014 | 6 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 287 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 365 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2015 | 476 | 0.030 |
Why?
|
| RNA Helicases | 1 | 2014 | 35 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2014 | 199 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2015 | 185 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 250 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1531 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 526 | 0.030 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 249 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2018 | 628 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 752 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 273 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2020 | 1351 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 104 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 181 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2705 | 0.030 |
Why?
|
| Gene Library | 1 | 2012 | 130 | 0.030 |
Why?
|
| STAT6 Transcription Factor | 1 | 2012 | 28 | 0.030 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2012 | 20 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2012 | 42 | 0.030 |
Why?
|
| Everolimus | 1 | 2012 | 40 | 0.030 |
Why?
|
| Chemokines | 1 | 2012 | 73 | 0.030 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2011 | 2 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2012 | 42 | 0.030 |
Why?
|
| Nitrophenols | 1 | 2011 | 11 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2012 | 64 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 744 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1673 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 78 | 0.030 |
Why?
|
| Bortezomib | 1 | 2011 | 76 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2011 | 55 | 0.020 |
Why?
|
| Acetylation | 1 | 2011 | 121 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 68 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 74 | 0.020 |
Why?
|
| North America | 1 | 2011 | 180 | 0.020 |
Why?
|
| Pyrazines | 1 | 2011 | 92 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 182 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 126 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Pyrroles | 1 | 2011 | 184 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 237 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2010 | 179 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 407 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 684 | 0.020 |
Why?
|
| Methotrexate | 1 | 2010 | 249 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2010 | 44 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2010 | 295 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 272 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 338 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 560 | 0.020 |
Why?
|
| Histones | 1 | 2011 | 311 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2011 | 300 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 261 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 371 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 134 | 0.020 |
Why?
|
| Temperature | 1 | 2010 | 396 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2010 | 281 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1139 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2601 | 0.020 |
Why?
|
| Exons | 1 | 2010 | 450 | 0.020 |
Why?
|
| Family | 1 | 2010 | 311 | 0.020 |
Why?
|
| Plasmids | 1 | 2009 | 287 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 1052 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2007 | 141 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2009 | 329 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2010 | 222 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2010 | 243 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2007 | 94 | 0.020 |
Why?
|
| Drug Design | 1 | 2007 | 124 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 1054 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 896 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 307 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 207 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 322 | 0.020 |
Why?
|
| United States | 1 | 2019 | 6672 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 1577 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2007 | 510 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 315 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 927 | 0.020 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2005 | 7 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 2005 | 32 | 0.020 |
Why?
|
| Flucytosine | 1 | 2005 | 11 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 64 | 0.020 |
Why?
|
| DNA Primers | 1 | 2005 | 543 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 363 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2005 | 434 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 5417 | 0.010 |
Why?
|
| Adolescent | 1 | 2010 | 8981 | 0.010 |
Why?
|